文献速递肿瘤 PET/CT神经核医学

非FDG-PET/CT在头颈癌中的应用

Role of Non-FDG-PET/CT in Head and Neck Cancer.
PubMed 文献 · Semin Nucl Med · 2020-08-07

头颈癌以鳞状细胞癌为主,18F-FDG-PET/CT已常规用于评估、治疗计划和预后判断。多种研究性非FDG示踪剂虽未取代FDG,但可提供肿瘤缺氧、氨基酸代谢和增殖等生物学信息。本文综述头颈癌中研究最多的非FDG-PET/CT示踪剂。

要点

  • 18F-FMISO等缺氧示踪剂可显示肿瘤缺氧灶,有助于靶向放疗抗拒区域。
  • 放射性标记氨基酸示踪剂在肿瘤摄取高而炎症组织摄取低,有助于鉴别放疗后炎症与残留/复发。
  • 18F-FLT可反映肿瘤增殖,治疗后摄取下降可早期提示治疗反应。

核心结论

  • 非FDG-PET/CT示踪剂目前未能取代18F-FDG-PET/CT常规临床实践,但可提供肿瘤生物学机制的重要补充信息。

研究设计与样本

  • 本文为综述,旨在综合头颈癌中研究最多的非FDG-PET/CT示踪剂相关文献。

主要发现

  • 缺氧特异性示踪剂如18F-FMISO可显示肿瘤缺氧灶,18F-FMISO是研究最多的缺氧示踪剂。
  • 其他缺氧示踪剂如18F-FAZA和18F-HX4也进行了类似评估。
  • 放射性标记氨基酸示踪剂在肿瘤细胞摄取增加而炎症组织摄取有限,有助于鉴别放疗后炎症与残留和/或复发疾病。
  • 18F-FLT通过核苷转运进入细胞内并磷酸化而滞留于肿瘤细胞,可作为肿瘤增殖指标,治疗后活性下降可早期提示治疗反应。

临床怎么用

  • 在治疗计划中可利用缺氧特异性PET示踪剂靶向放疗抗拒的缺氧肿瘤灶。
  • 利用氨基酸PET示踪剂鉴别放疗后炎症与残留和/或复发疾病。
  • 利用18F-FLT摄取变化早期评估治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Head and neck cancers are commonly encountered malignancies in the United States, of which the majority are attributed to squamous cell carcinoma. 18F-FDG-PET/CT has been well established in the evaluation, treatment planning, prognostic implications of these tumors and is routinely applied for the management of patients with these cancers. Many alternative investigational PET radiotracers have been extensively studied in the evaluation of these tumors. Although these radiotracers have not been able to replace 18F-FDG-PET/CT in routine clinical practice currently, they may provide important additional information about the biological mechanisms of these tumors, such as foci of tumor hypoxia as seen on hypoxia specific PET radiotracers such as 18F-Fluoromisonidazole (18F-FMISO), which could be useful in targeting radioresistant hypoxic tumor foci when treatment planning. There are multiple other hypoxia-specific PET radiotracers such as 18F-Fluoroazomycinarabinoside (FAZA), 18F-Flortanidazole (HX4), which have been evaluated similarly, of which 18F-Fluoromisonidazole (18F-FMISO) has been the most investigated. Other radiotracers frequently studied in the evaluation of these tumors include radiolabeled amino acid PET radiotracers, which show increased uptake in tumor cells with limited uptake in inflammatory tissue, which can be useful especially in differentiating postradiation inflammation from residual and/or recurrent disease. 18F-Fluorothymidine (FLT) is localized intracellularly by nucleoside transport and undergoes phosphorylation thereby being retained within tumor cells and can serve as an indicator of tumor proliferation. Decrease in radiotracer activity following treatment can be an early indicator of treatment response. This review aims at synthesizing the available literature on the most studied non-FDG-PET/CT in head and neck cancer.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Marcus C, Subramaniam RM. Role of Non-FDG-PET/CT in Head and Neck Cancer. Semin Nucl Med. 2020. PMID: 33246541. doi:10.1053/j.semnuclmed.2020.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。